These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18789721)

  • 1. Preparation and use of therapeutic antibodies primarily of human origin.
    Stiehm ER; Keller MA; Vyas GN
    Biologicals; 2008 Nov; 36(6):363-74. PubMed ID: 18789721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody production: polyclonal-derived biotherapeutics.
    Newcombe C; Newcombe AR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):2-7. PubMed ID: 16893686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of human immunoglobulin therapy.
    Stiehm ER
    Transfus Med Rev; 2013 Jul; 27(3):171-8. PubMed ID: 23835249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-directed therapy: past, present, and future.
    Gelfand EW
    J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S111-6. PubMed ID: 11586277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expanding role of therapeutic antibodies.
    Salemi S; Markovic M; Martini G; D'Amelio R
    Int Rev Immunol; 2015 May; 34(3):202-64. PubMed ID: 24471447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic antibodies in multiple sclerosis.
    Goebels N; Becher B
    Neurodegener Dis; 2008; 5(1):5-7. PubMed ID: 18075268
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunoprophylaxis of respiratory infections].
    Dreffier C; Ramisse F; Alonso JM
    Med Sci (Paris); 2004 Nov; 20(11):999-1003. PubMed ID: 15525495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonals antibodies: a recent and major therapeutic advance].
    Paintaud G; Lejarre F; Ternant D; Goupille P; Watier H
    Therapie; 2009; 64(1):1-7. PubMed ID: 19463247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody.
    Bazin R; Lemieux R; Tremblay T
    Br J Haematol; 2006 Oct; 135(1):97-100. PubMed ID: 16925577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacture of recombinant polyclonal antibodies.
    Rasmussen SK; Rasmussen LK; Weilguny D; Tolstrup AB
    Biotechnol Lett; 2007 Jun; 29(6):845-52. PubMed ID: 17310321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aseptic meningitis and abducens nerve palsy as a serious side effect of high dose intravenous immunoglobulin used in a patient with renal transplantation.
    Wright SE; Shaikh ZH; Castillo-Lugo JA; Tanriover B
    Transpl Infect Dis; 2008 Jul; 10(4):294-7. PubMed ID: 18086279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy in non-allergic diseases].
    Español T
    Allergol Immunopathol (Madr); 2000; 28(3):107-9. PubMed ID: 10867379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of antibodies in the treatment of infectious diseases.
    Chan CE; Chan AH; Hanson BJ; Ooi EE
    Singapore Med J; 2009 Jul; 50(7):663-72; quiz 673. PubMed ID: 19644620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of intravenous immunoglobulins.
    Nydegger UE; Mohacsi PJ; Escher R; Morell A
    Vox Sang; 2000; 78 Suppl 2():191-5. PubMed ID: 10938951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events associated with intravenous immunoglobulin therapy.
    Hamrock DJ
    Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction.
    Fuchs S; Feferman T; Zhu KY; Meidler R; Margalit R; Wang N; Laub O; Souroujon MC
    Ann N Y Acad Sci; 2007 Sep; 1110():550-8. PubMed ID: 17911471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.